Findings

What do systematic reviews say?

27 questions · 27 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 40.7%GRADE not reported 0 · 0%Very low 3 · 11.1%Low 13 · 48.1%Moderate 0 · 0%High 0 · 0%

Low molecular weight heparin vs unfractionated heparin

All‐cause mortality · patients with cancer with venous thromboembolism

Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.66 [0.4, 1.1]
5 studies · 418 participants
Low

Low molecular weight heparin vs unfractionated heparin

Recurrent VTE · patients with cancer with venous thromboembolism

Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.69 [0.27, 1.76]
3 studies · 422 participants
Low

Low molecular weight heparin vs unfractionated heparin

Major bleeding · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Quality of life ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Thrombocytopenia · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found